Prothena Corporation PLC (NASDAQ:PRTA) – Wedbush dropped their FY2017 earnings per share (EPS) estimates for shares of Prothena Corporation PLC in a note issued to investors on Monday. Wedbush analyst D. Nierengarten now expects that the biotechnology company will post earnings per share of ($4.28) for the year, down from their prior forecast of ($3.94). Wedbush currently has a “Neutral” rating and a $55.00 target price on the stock. Wedbush also issued estimates for Prothena Corporation PLC’s Q4 2017 earnings at ($1.45) EPS, Q1 2018 earnings at ($1.45) EPS, Q2 2018 earnings at ($1.35) EPS, Q3 2018 earnings at ($1.16) EPS, Q4 2018 earnings at ($1.05) EPS, FY2018 earnings at ($4.99) EPS, FY2019 earnings at ($4.70) EPS, FY2020 earnings at ($4.37) EPS and FY2021 earnings at ($2.35) EPS.

Prothena Corporation PLC (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.41) by $0.04. Prothena Corporation PLC had a negative net margin of 562.19% and a negative return on equity of 34.40%. The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.28 million. During the same period in the prior year, the firm earned ($1.26) earnings per share. The firm’s revenue for the quarter was down 33.6% compared to the same quarter last year.

WARNING: “Prothena Corporation PLC (PRTA) Forecasted to Earn FY2017 Earnings of ($4.28) Per Share” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/prothena-corporation-plc-prta-forecasted-to-earn-fy2017-earnings-of-4-28-per-share/1723183.html.

Several other equities analysts also recently issued reports on the stock. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $70.00 price objective on shares of Prothena Corporation PLC in a report on Thursday, November 9th. Deutsche Bank AG set a $73.00 price target on shares of Prothena Corporation PLC and gave the stock a “buy” rating in a report on Monday, October 23rd. ValuEngine downgraded shares of Prothena Corporation PLC from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $100.00 price target on shares of Prothena Corporation PLC in a report on Monday, October 2nd. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and issued a $75.00 price target on shares of Prothena Corporation PLC in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $76.75.

Shares of Prothena Corporation PLC (NASDAQ:PRTA) opened at $45.85 on Wednesday. Prothena Corporation PLC has a 1 year low of $44.43 and a 1 year high of $70.00.

In other Prothena Corporation PLC news, insider Tara Nickerson sold 17,500 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $63.60, for a total value of $1,113,000.00. Following the transaction, the insider now owns 19,500 shares in the company, valued at approximately $1,240,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gene G. Kinney sold 2,800 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $70.00, for a total value of $196,000.00. Following the completion of the transaction, the insider now owns 5,593 shares in the company, valued at approximately $391,510. The disclosure for this sale can be found here. Insiders have sold a total of 29,424 shares of company stock worth $1,922,787 in the last quarter. Insiders own 3.10% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Fieldpoint Private Securities LLC purchased a new position in shares of Prothena Corporation PLC during the 3rd quarter worth $162,000. California Public Employees Retirement System raised its holdings in shares of Prothena Corporation PLC by 1.8% during the 3rd quarter. California Public Employees Retirement System now owns 60,700 shares of the biotechnology company’s stock worth $3,932,000 after acquiring an additional 1,100 shares during the period. Sectoral Asset Management Inc raised its holdings in shares of Prothena Corporation PLC by 29.7% during the 3rd quarter. Sectoral Asset Management Inc now owns 195,909 shares of the biotechnology company’s stock worth $12,689,000 after acquiring an additional 44,863 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in shares of Prothena Corporation PLC by 5.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 172,578 shares of the biotechnology company’s stock worth $11,178,000 after acquiring an additional 8,897 shares during the period. Finally, Legal & General Group Plc raised its holdings in shares of Prothena Corporation PLC by 15.0% during the 3rd quarter. Legal & General Group Plc now owns 15,761 shares of the biotechnology company’s stock worth $1,020,000 after acquiring an additional 2,053 shares during the period.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Earnings History and Estimates for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.